Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells

Overview

Journal Stem Cells Int

Publisher Wiley

Specialty Cell Biology

Date 2016 Jun 14

PMID 27293445

Citations 15

Authors

Shujing Li

Xianyun Wang

Jing Li

Jun Zhang

Fan Zhang

Jie Hu

Yixin Qi

Baoyong Yan

Quanhai Li

Affiliations

Soon will be listed here.

Abstract

Ischemic diseases are a group of diseases, including ischemic cerebrovascular disease, ischemic cardiomyopathy (ICM), and diabetic foot as well as other diseases which are becoming a leading cause of morbidity and mortality in the whole world. Mesenchymal stem cells (MSCs) have been used to treat a variety of ischemic diseases in animal models and clinical trials. Lots of recent publications demonstrated that MSCs therapy was safe and relieved symptoms in patients of ischemic disease. However, many factors could influence therapeutic efficacy including route of delivery, MSCs' survival and residential rate in vivo, timing of transplantation, particular microenvironment, and patient's clinical condition. In this review, the current status, therapeutic potential, and the detailed factors of MSCs-based therapeutics for ischemic cerebrovascular disease, ICM, and diabetic foot are presented and discussed. We think that MSCs transplantation would constitute an ideal option for patients with ischemic diseases.

Citing Articles

Ischemic Brain Stroke and Mesenchymal Stem Cells: An Overview of Molecular Mechanisms and Therapeutic Potential.

Jingli Y, Jing W, Saeed Y Stem Cells Int. 2022; 2022:5930244.

PMID: 35663353 PMC: 9159823. DOI: 10.1155/2022/5930244.

Strategies to Improve the Quality and Freshness of Human Bone Marrow-Derived Mesenchymal Stem Cells for Neurological Diseases.

Lee D, Lee S, Kwon D, Nithiyanandam S, Lee M, Hwang J Stem Cells Int. 2021; 2021:8444599.

PMID: 34539792 PMC: 8445711. DOI: 10.1155/2021/8444599.

Mesenchymal Stem Cell Transplantation for Ischemic Diseases: Mechanisms and Challenges.

Van Nguyen T, Vu N, Van Pham P Tissue Eng Regen Med. 2021; 18(4):587-611.

PMID: 33884577 PMC: 8325739. DOI: 10.1007/s13770-021-00334-3.

Mesenchymal Stem Cell-Mediated Mitochondrial Transfer: a Therapeutic Approach for Ischemic Stroke.

Lu M, Guo J, Wu B, Zhou Y, Wu M, Farzaneh M Transl Stroke Res. 2020; 12(2):212-229.

PMID: 32975692 DOI: 10.1007/s12975-020-00853-6.

Silica-Coated Magnetic Nanoparticles Decrease Human Bone Marrow-Derived Mesenchymal Stem Cell Migratory Activity by Reducing Membrane Fluidity and Impairing Focal Adhesion.

Shin T, Lee D, Ketebo A, Lee S, Manavalan B, Basith S Nanomaterials (Basel). 2019; 9(10).

PMID: 31627375 PMC: 6835988. DOI: 10.3390/nano9101475.

References

Wang Y, Dan Q, Wang Q, Zhou N, Jin X, Hou Z . [Human umbilic mesenchymal stromal cells repairs diabetic foot in rats associated with VEGF expressional change]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2014; 45(1):29-33. View

Schiavetta A, Maione C, Botti C, Marino G, Lillo S, Garrone A . A phase II trial of autologous transplantation of bone marrow stem cells for critical limb ischemia: results of the Naples and Pietra Ligure Evaluation of Stem Cells study. Stem Cells Transl Med. 2012; 1(7):572-8. PMC: 3659723. DOI: 10.5966/sctm.2012-0021. View

Maxson S, Lopez E, Yoo D, Danilkovitch-Miagkova A, Leroux M . Concise review: role of mesenchymal stem cells in wound repair. Stem Cells Transl Med. 2012; 1(2):142-9. PMC: 3659685. DOI: 10.5966/sctm.2011-0018. View

Kim J, Park S, Park S, Choi J, Xia Y, Sung J . The pivotal role of reactive oxygen species generation in the hypoxia-induced stimulation of adipose-derived stem cells. Stem Cells Dev. 2011; 20(10):1753-61. PMC: 3182032. DOI: 10.1089/scd.2010.0469. View

Das R, Jahr H, van Osch G, Farrell E . The role of hypoxia in bone marrow-derived mesenchymal stem cells: considerations for regenerative medicine approaches. Tissue Eng Part B Rev. 2009; 16(2):159-68. DOI: 10.1089/ten.TEB.2009.0296. View

Cavallari G, Olivi E, Bianchi F, Neri F, Foroni L, Valente S . Mesenchymal stem cells and islet cotransplantation in diabetic rats: improved islet graft revascularization and function by human adipose tissue-derived stem cells preconditioned with natural molecules. Cell Transplant. 2012; 21(12):2771-81. DOI: 10.3727/096368912X637046. View

Chen S, Fang W, Qian J, Ye F, Liu Y, Shan S . Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chin Med J (Engl). 2004; 117(10):1443-8. View

Li H, Chen Y, Chen S, Kao C, Tseng L, Lo W . Induction of insulin-producing cells derived from endometrial mesenchymal stem-like cells. J Pharmacol Exp Ther. 2010; 335(3):817-29. DOI: 10.1124/jpet.110.169284. View

Gnecchi M, Danieli P, Cervio E . Mesenchymal stem cell therapy for heart disease. Vascul Pharmacol. 2012; 57(1):48-55. DOI: 10.1016/j.vph.2012.04.002. View

10.

Xia N, Xu J, Zhao N, Zhao Q, Li M, Cheng Z . Human mesenchymal stem cells improve the neurodegeneration of femoral nerve in a diabetic foot ulceration rats. Neurosci Lett. 2015; 597:84-9. DOI: 10.1016/j.neulet.2015.04.038. View

11.

Surder D, Manka R, Cicero V, Moccetti T, Rufibach K, Soncin S . Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function. Circulation. 2013; 127(19):1968-79. DOI: 10.1161/CIRCULATIONAHA.112.001035. View

12.

Losordo D, Henry T, Davidson C, Lee J, Costa M, Bass T . Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011; 109(4):428-36. PMC: 3190575. DOI: 10.1161/CIRCRESAHA.111.245993. View

13.

Michler R . Stem cell therapy for heart failure. Methodist Debakey Cardiovasc J. 2013; 9(4):187-94. PMC: 3846071. DOI: 10.14797/mdcj-9-4-187. View

14.

Zhang Y, Shen W, Hua J, Lei A, Lv C, Wang H . Pancreatic islet-like clusters from bone marrow mesenchymal stem cells of human first-trimester abortus can cure streptozocin-induced mouse diabetes. Rejuvenation Res. 2011; 13(6):695-706. DOI: 10.1089/rej.2009.1016. View

15.

Heldman A, DiFede D, Fishman J, Zambrano J, Trachtenberg B, Karantalis V . Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2013; 311(1):62-73. PMC: 4111133. DOI: 10.1001/jama.2013.282909. View

16.

OLoughlin A, Kulkarni M, Creane M, Vaughan E, Mooney E, Shaw G . Topical administration of allogeneic mesenchymal stromal cells seeded in a collagen scaffold augments wound healing and increases angiogenesis in the diabetic rabbit ulcer. Diabetes. 2013; 62(7):2588-94. PMC: 3712062. DOI: 10.2337/db12-1822. View

17.

Williams A, Trachtenberg B, Velazquez D, McNiece I, Altman P, Rouy D . Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res. 2011; 108(7):792-6. PMC: 3390160. DOI: 10.1161/CIRCRESAHA.111.242610. View

18.

Hare J, Traverse J, Henry T, Dib N, Strumpf R, Schulman S . A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009; 54(24):2277-86. PMC: 3580848. DOI: 10.1016/j.jacc.2009.06.055. View

19.

Zonta S, De Martino M, Bedino G, Piotti G, Rampino T, Gregorini M . Which is the most suitable and effective route of administration for mesenchymal stem cell-based immunomodulation therapy in experimental kidney transplantation: endovenous or arterial?. Transplant Proc. 2010; 42(4):1336-40. DOI: 10.1016/j.transproceed.2010.03.081. View

20.

Anzalone R, Lo Iacono M, Loria T, Di Stefano A, Giannuzzi P, Farina F . Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Stem Cell Rev Rep. 2010; 7(2):342-63. DOI: 10.1007/s12015-010-9196-4. View